A study that involved over 17,000 patients aged 45 and above with a BMI of 27 or higher, who had existing cardiovascular disease but no history of diabetes, has shown significant results. The participants were divided into two groups: one received semaglutide while the other received a placebo. After an average follow-up of almost 40 months, the treatment group experienced a 20% reduction in the risk of cardiovascular disease compared to the placebo group.

The drug also resulted in significant weight loss (9.4% in patients compared to 0.88% in the placebo) and a decrease in waist circumference. According to Avi Karsik, director of the obesity clinic at DMC center for diabetes, endocrinology and obesity treatment, this study’s implications are far-reaching. Obesity affects millions globally and is a critical factor in cardiovascular diseases. This study demonstrates that semaglutide can effectively deal with cardiovascular risks among a significant segment of the population that was not previously considered for such treatments.

While these findings represent a significant step forward in fighting cardiovascular disease, it highlights the need for equity in accessing such treatments and continuing to focus on preventive strategies against obesity.